NCT04316546 2026-03-11
MK-7075 (Miransertib) in Proteus Syndrome
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
4 trialsNCT02594215 2022-06-30
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT03317366 2021-08-06
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
No longer available
NCT01473095 2017-10-23
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed